Expert opinion on drug metabolism & toxicology最新文献

Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques. 使用机器学习技术评估药物特性在药物性肝损伤严重程度中的作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-06 DOI: 10.1080/17425255.2025.2525470

Irene Victoria Bermúdez-Pérez, Ismael Alvarez-Alvarez, Inmaculada Medina-Cáliz, Mercedes Robles-Diaz, Hao Niu, Minjun Chen, Raúl J Andrade, Mª Isabel Lucena, Camilla Stephens, Andrés Gonzalez-Jimenez

{"title":"Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques.","authors":"Irene Victoria Bermúdez-Pérez, Ismael Alvarez-Alvarez, Inmaculada Medina-Cáliz, Mercedes Robles-Diaz, Hao Niu, Minjun Chen, Raúl J Andrade, Mª Isabel Lucena, Camilla Stephens, Andrés Gonzalez-Jimenez","doi":"10.1080/17425255.2025.2525470","DOIUrl":"10.1080/17425255.2025.2525470","url":null,"abstract":"Background: Drug-induced liver injury (DILI) is a complex liver pathology modulated by multiple factors, most of which remain unknown. Previous studies have suggested that concomitant medications and patient characteristics play an important role as modulators of this disease. This study aimed to determine the most relevant concomitant medications and patient characteristics that influence the severity of idiosyncratic DILI.Methods: Two clinical databases, discovery and validation, were analyzed to evaluate host and drug properties. Predictive algorithms, elastic net regression model and logistic regression model, were implemented using R, both achieving ROC AUC > 0.7.Results: The findings revealed the existence of significant relationship between DILI severity and multiple factors. These factors included: hepatocellular injury, hydrophobic drugs with logP > 3 (octanol-water partition coefficient), and the use of concomitant medications containing halogen compounds or heterorings when taken together with culprit drugs with significant hepatic metabolism.Conclusions: These findings offer valuable insights into predicting the severity of DILI. By identifying the key factors that influence the severity of DILI, it would be possible for healthcare providers to predict the severity of damage in a patient with DILI. This enables early interventions in cases of DILI, thus subsequently reducing its negative effects.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the 'exposome' and human health. 从作为非p450醛氧化酶的醛脱氢酶中吸取的教训：对“接触者”和人类健康的影响。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-02 DOI: 10.1080/17425255.2025.2524872

Athina Lisgara, David C Thompson, Daniel W Nebert, Vasilis Vasiliou

{"title":"Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the 'exposome' and human health.","authors":"Athina Lisgara, David C Thompson, Daniel W Nebert, Vasilis Vasiliou","doi":"10.1080/17425255.2025.2524872","DOIUrl":"https://doi.org/10.1080/17425255.2025.2524872","url":null,"abstract":"Introduction: Aldehyde dehydrogenases (ALDHs) are critical enzymes that protect against cellular damage by metabolizing reactive aldehydes derived from both endogenous processes and environmental exposures. Although cytochrome P450 enzymes dominate metabolic toxicology discussions, the non-P450 ALDH superfamily plays a unique underrecognized role in mitigating the health impacts of the exposome - the totality of lifetime environmental exposures.Areas covered: This Special Report highlights key insights from recent research on ALDHs, with a focus on their enzymatic diversity, disease-relevant polymorphisms, detoxication functions, and potential as therapeutic targets and clinical biomarkers. A comprehensive review is provided on how ALDHs influence individual susceptibility to environmental stressors, support redox balance, and serve as important mediators in cancer, cardiovascular and neurodegenerative diseases. Clinical implications of ALDH polymorphisms are discussed in the context of precision environmental health. Whereas ALDHs are generally known for their role in detoxifying harmful aldehydes, some ALDHs have been shown to activate other molecules instead. For example, ALDH2 can activate nitroglycerin to nitric oxide-related species - critical for cardioprotective signaling; a process distinct from their typical detoxication function.Expert opinion: Integrating ALDH biology into exposome research offers a powerful path toward precision risk assessment and possible interventions. Given their public health and clinical relevance, future efforts should prioritize mapping ALDH-exposome interactions, genetic screening, and developing ALDH-targeted interventions.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using ¹⁴C-radiolabelled techniques. 使用14c放射性标记技术的新型钾竞争酸阻滞剂替哥拉赞的人体质量平衡和代谢物谱。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-05-13 DOI: 10.1080/17425255.2025.2505637

Yicong Bian, Jinjie Yuan, Sheng Ma, Jiang Nan, Zheming Gu, Hao Feng, Zhenwen Yu, Zhenteng Liu, Fang Xie, Yinghui Wang, Chengxin Liu, Hua Zhang, Liyan Miao

{"title":"Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using 14C-radiolabelled techniques.","authors":"Yicong Bian, Jinjie Yuan, Sheng Ma, Jiang Nan, Zheming Gu, Hao Feng, Zhenwen Yu, Zhenteng Liu, Fang Xie, Yinghui Wang, Chengxin Liu, Hua Zhang, Liyan Miao","doi":"10.1080/17425255.2025.2505637","DOIUrl":"10.1080/17425255.2025.2505637","url":null,"abstract":"Background: Tegoprazan (LXI-15028), a novel potassium-competitive acid blocker, has shown great efficacy in treating acid-related disorders. However, its metabolic and excretion characteristics are not fully understood.Research design and methods: A single oral dose of 50 mg/150 μCi [14C]tegoprazan was administered to six healthy subjects. Blood, urine and fecal samples were collected and measured for total radioactivity (TRA), tegoprazan and metabolites. Its safety was also assessed.Results: The maximum concentrations (Cmax) of tegoprazan and TRA in plasma were 634 ng/mL and 990 ng eq./mL, respectively, at 0.5 h post dose. Tegoprazan and its N-demethylation metabolite (M1) were the major drug-related compounds in plasma, accounting for 34.84% and 40.10% of TRA, respectively. The half-life (t1/2) of TRA (8.72 h) was longer than that of tegoprazan (4.33 h) in plasma, indicating slower metabolite elimination. Tegoprazan was excreted through both the urine (50.51 ± 3.35%) and feces (47.26 ± 3.06%). The main metabolic pathways of tegoprazan are demethylation, oxidation, glucuronidation and sulfation. There were no serious adverse events observed in this study.Conclusions: Tegoprazan is widely metabolized and excreted completely in humans. Tegoprazan and M1 were the primary compounds present in the circulation.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05883306.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"897-907"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study. 非专利和品牌伊鲁替尼胶囊在中国健康志愿者禁食和进食条件下的生物等效性：一项随机、四期、完全重复的交叉研究

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-04-28 DOI: 10.1080/17425255.2025.2496459

Rong Zhang, Rui Chong, Shaomei Yang, Kun He, Qing Wen

{"title":"Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study.","authors":"Rong Zhang, Rui Chong, Shaomei Yang, Kun He, Qing Wen","doi":"10.1080/17425255.2025.2496459","DOIUrl":"10.1080/17425255.2025.2496459","url":null,"abstract":"Background: The aim of this study was to evaluate the bioequivalence of the test and reference products of ibrutinib capsule (140 mg).Research design and methods: This was a fully replicated crossover study that included 100 healthy Chinese volunteers (50 in the fasting BE study and 50 in the fed BE study). Subjects were assigned to receive a single dose of test or reference product in each treatment period. The bioequivalence of main PK parameters (Cmax, AUC0-t, and AUC0-∞) was evaluated using either the average bioequivalence (ABE) approach or the reference-scaled average bioequivalence (RSABE) approach, depending on the within-subject standard deviation of the reference product (SWR) estimated in the study.Results: RSABE approach was applied to Cmax as the corresponding SWR value exceeded the cutoff value of 0.294, while ABE approach was applied to AUC0-t and AUC0-∞ as the corresponding SWR values were less than 0.294. All three PK parameters (Cmax, AUC0-t, and AUC0-∞) met the bioequivalence acceptance criteria in both fasting and fed studies.Conclusions: The test and reference products of ibrutinib capsule are bioequivalent under both fasting and fed conditions. This study also confirmed high intra-subject variability for the Cmax of ibrutinib.Clinical trial registration: http://www.chinadrugtrials.org.cn/index.html identifier is CTR20202168.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"875-883"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury. 药物代谢酶和转运体及其在药物性肝损伤发展中的作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-06-09 DOI: 10.1080/17425255.2025.2514537

AyoOluwa O Olubamiwa, Jingyi Ma, Patrice Dehanne, Catherine Noban, Yeliz Angın, Olivier Barberan, Minjun Chen

{"title":"Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury.","authors":"AyoOluwa O Olubamiwa, Jingyi Ma, Patrice Dehanne, Catherine Noban, Yeliz Angın, Olivier Barberan, Minjun Chen","doi":"10.1080/17425255.2025.2514537","DOIUrl":"10.1080/17425255.2025.2514537","url":null,"abstract":"Introduction: Drug-induced liver injury (DILI) poses a significant challenge to drug development and human healthcare. The complex mechanisms underlying DILI make it challenging to accurately predict its occurrence, often leading to substantial financial losses from failed drug development projects and drug withdrawals. Growing evidence suggests that drug-metabolizing enzymes and transporters (DMETs) play a critical role in the development of DILI.Areas covered: In this review, we explore findings about the contributions of DMETs to DILI, with a focus on the studies examining genetic polymorphisms and their interactions with drugs. Additionally, we highlight the roles of DMETs in the development of predictive models for assessing DILI potential and in uncovering the mechanisms involved in DILI.Expert opinion: As new approach methods (NAMs) for assessing and predicting drug toxicity gain more prominence, it is imperative to better understand the adverse outcome pathways (AOPs) that underpin these methods. DMETs largely play a pivotal role in the molecular initiating events of DILI-related AOPs. Further research is needed to characterize DILI-related AOP networks and enhance the predictive performance of NAMs for assessing DILI risk.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"755-768"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers. rev - erba修饰剂对环磷酰胺肝毒性的调节作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-04-11 DOI: 10.1080/17425255.2025.2490741

Jinyi Wang, Jialu Cui, Tingying Hao, Qi Zhang, Yutong Chen, Lianxia Guo, Yongbin Tong, Dong Dong

{"title":"Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers.","authors":"Jinyi Wang, Jialu Cui, Tingying Hao, Qi Zhang, Yutong Chen, Lianxia Guo, Yongbin Tong, Dong Dong","doi":"10.1080/17425255.2025.2490741","DOIUrl":"10.1080/17425255.2025.2490741","url":null,"abstract":"Introduction: Cyclophosphamide (CPA) is a widely used broad-spectrum antitumor drug with severe hepatotoxicity. Finding an effective way to mitigate the hepatotoxicity caused by CPA is a challenge in its clinical application.Methods: In Rev-erbα knockout and wild-type mice, hepatotoxicity was evaluated by ALT, AST, and histopathological scores 4-h post dose of CPA (i.p. 300 mg/kg). CYP2B10 expression and pharmacokinetic behavior of CPA were also detected. SR9009 (i.p. 10 mg/kg) and Berberine (BBR, i.p. 50 mg/kg) were pre-administered to mice. Then, the measurements were carried out following the same procedures as previous. The regulation effects of SR9009 and BBR on CYP2B10 were validated using Hepa-1c1c7 cells.Results: Firstly, REV-ERBα negatively regulated CPA-induced hepatotoxicity by altering the expression of CYP2B10 and CPA pharmacokinetics. Secondly, REV-ERBα agonists, SR9009 and BBR, increased REV-ERBα expression and alleviated hepatic toxicity of CPA. Furthermore, both SR9009 and BBR reduced expression of CYP2B10 and REV-ERBα target gene Bmal1 both in vivo and in vitro.Conclusions: REV-ERBα agonists can significantly attenuate the hepatotoxicity of CPA by regulating CYP2B10. The discovery of REV-ERBα as novel regulator for CYP2B10 will help to establish new targets to improve drug efficacy or reduce toxicity.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"885-895"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far. 老年人的药代动力学和药效学改变：我们目前所知道的。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-05-11 DOI: 10.1080/17425255.2025.2503848

Arduino A Mangoni, Richard J Woodman, Elzbieta A Jarmuzewska

{"title":"Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far.","authors":"Arduino A Mangoni, Richard J Woodman, Elzbieta A Jarmuzewska","doi":"10.1080/17425255.2025.2503848","DOIUrl":"10.1080/17425255.2025.2503848","url":null,"abstract":"Introduction: Healthcare professionals face increasing challenges when managing older patients, a group characterized by significant interindividual variability in comorbidity patterns, homeostatic capacity, frailty status, cognitive function, and life expectancy. Complex therapeutic decisions may increase the risk of inappropriate polypharmacy, drug-drug, and drug-disease interactions in the context of age-associated pharmacokinetic and pharmacodynamic alterations, with consequent drug accumulation and toxicity.Areas covered: This state-of-the-art narrative review article summarizes and critically appraises the results of original research studies and reviews published in PubMed, Scopus, and Web of Science, from inception to 9 April 2025, on age-associated changes in critical organs and systems and relevant pharmacokinetic and pharmacodynamic alterations. It also discusses the emerging role of frailty and the gut microbiota in influencing such alterations and the potential utility of machine learning techniques in identifying new signals of drug efficacy and toxicity in older patients.Expert opinion: The available knowledge regarding specific age-associated pharmacokinetic and pharmacodynamic alterations applies to a limited number of drugs, some of which are not frequently prescribed in contemporary practice. Future studies investigating a wider range of drugs and their patterns of use will likely enhance therapeutic efficacy and minimize toxicity in the older patient population.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"811-829"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lazertinib: a novel EGFR-TKI therapy for non-small cell lung cancer. Lazertinib：一种治疗非小细胞肺癌的新型EGFR-TKI疗法。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-05-21 DOI: 10.1080/17425255.2025.2507404

Dhairavi Shah, Dhaara Shah, Suzy Ndandji, Supratik Kar

{"title":"Lazertinib: a novel EGFR-TKI therapy for non-small cell lung cancer.","authors":"Dhairavi Shah, Dhaara Shah, Suzy Ndandji, Supratik Kar","doi":"10.1080/17425255.2025.2507404","DOIUrl":"10.1080/17425255.2025.2507404","url":null,"abstract":"Introduction: Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for 85% of cases worldwide. Despite advancements in treatment, many patients are diagnosed at advanced stages, and resistance to therapy, such as EGFR inhibitors, remains a significant challenge. Lazertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) developed by Yuhan Corporation and Janssen Biotech, targets EGFR mutations, including T790M, which confer resistance to earlier-generation TKIs.Areas covered: This review explores lazertinib's development, mechanism of action, clinical efficacy, and safety profile. Preclinical studies demonstrated its superior selectivity for mutant EGFR and blood-brain barrier penetration compared to osimertinib. Clinical trials highlight its efficacy as monotherapy and in combination with amivantamab, showing improved progression-free survival and response duration in patients with advanced NSCLC.Expert opinion: Lazertinib represents a promising advance in the treatment of EGFR-mutated NSCLC, particularly for patients with brain metastases or resistance to previous EGFR TKIs. However, emerging resistance mutations, such as C797S, underscore the need for continued innovation, including combination therapies and fourth-generation TKIs. Future research must address these challenges to optimize treatment outcomes for NSCLC patients.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"789-800"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical perspectives on addressing hepatotoxicity during clinical candidate selection. 临床候选药物选择过程中处理肝毒性的实践观点。

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1080/17425255.2025.2516048

Adrian S Ray

引用次数: 0

A comparative study on the consistency of different decision support software systems from the perspective of potential drug-drug interactions in intensive care unit patients. 重症监护病房患者药物-药物潜在相互作用视角下不同决策支持软件系统一致性比较研究

Expert opinion on drug metabolism & toxicology Pub Date : 2025-07-01 Epub Date: 2025-05-27 DOI: 10.1080/17425255.2025.2511961

Furong Han, Xiao Cheng, Yiman Li, Jie Bai, Liming Dong, Jiawei Wang

{"title":"A comparative study on the consistency of different decision support software systems from the perspective of potential drug-drug interactions in intensive care unit patients.","authors":"Furong Han, Xiao Cheng, Yiman Li, Jie Bai, Liming Dong, Jiawei Wang","doi":"10.1080/17425255.2025.2511961","DOIUrl":"10.1080/17425255.2025.2511961","url":null,"abstract":"Background: In intensive care units (ICU), the issue of drug-drug interactions (DDIs) is becoming increasingly prominent, and these interactions can lead to adverse drug reactions, therapeutic failure, or altered drug efficacy. This study aimed to assess the frequency and attributes of potential drug-drug interactions (pDDIs) and the consistency of different decision support software in ICU patients.Research design and methods: A cross-sectional study was conducted in a tertiary hospital. The consistency of different decision support software was assessed using the Kendall W coefficient, Cohen's kappa, Cronbach's Alpha, Fleiss Kappa, Intraclass correlation coefficient and Gwet's AC1.Results: A total of 897 prescriptions from 290 patients were evaluated. The total number of pDDIs identified varied significantly across platforms, ranging from 134 to 213. Inter-platform agreement on severity classification was poor (Gwet's AC1 = 0.32, ICC = 0.41).Conclusions: This observational investigation revealed marked variability across clinical decision platforms regarding both quantitative and qualitative aspects of pDDIs identification in critical care populations, underscoring the imperative to establish unified protocols for pDDIs classification and implement dynamic DDI database maintenance.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"865-873"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0